Treatment
|
Triglycerides (mg/dl)
|
Total cholesterol (mg/dl)
|
HDL-cholesterol (mg/dl)
|
LDL-cholesterol (mg/dl)
|
Atherogenic index
|
---|
Control
|
53.48 ± 3.36
|
50.63 ± 2.07
|
48.76 ± 3.13
|
5.51 ± 3.68
|
1.06 ± 0.31
|
L-NAME
|
81.10 ± 3.80β
|
83.13 ± 4.02γ
|
17.57 ± 2.82β
|
38.52 ± 4.29β
|
5.35 ± 0.48γ
|
L-N + Capto
|
45.74 ± 3.36**
|
48.12 ± 2.09***
|
40.40 ± 3.32**
|
4.50 ± 3.96***
|
1.50 ± 0.70***
|
L-N + MECZ
|
50.16 ± 3.33*
|
56.46 ± 5.29***
|
42.26 ± 3.83**
|
9.50 ± 3.08***
|
1.41 ± 0.18***
|
- n = 5; βp < 0.01 and γp < 0.001 significantly different compared to the control; *p < 0.05, **p < 0.01 and ***p < 0.001 significantly different compared to L-NAME. L-NAME group received only L-NAME 40 mg/kg/day. L-N + Capto received L-NAME plus captopril (20 mg/kg/day) while L-N + MECZ received L-NAME plus extract (300 mg/kg/day).